Some biotech companies lose funding
When the financial meltdown knocked on the door of the global financial market, many thought that biotech and related fields won’t be affected at all. However, they were wrong. It may be true that biotech companies are fine when compared to other companies from other industry branches, but they also suffered a certain loss. Some of the companies even sought bankruptcy protection. Why? Because their “financial suppliers” cancelled the funding.
As an example, let’s take Advanced Cell Technology, a company who was granted a financial injection of $3 billion for stem cell research. They expanded their units to Alameda, California. However, they had to close it down. “Our financial suppliers have been cutting back and hunkering down.” said Daniel Schustak, company’s spokesman.
Another company called Avigen, Inc. is about to let go 70% of their workers because clinical trials they’ve been working on have failed to deliver, thus making the funding uncertain. Now the company is looking for buyers for their two new drugs — for nerve pain and hemophilia. “A lot of people are calling us, but we have nothing finalized yet.” said Michael Coffee, an Avigen representative.
What does this mean for an ordinary man who is just looking to invest some money? Wondering how to earn money in this financial storm? Experts keep saying that this is the time to buy… But what to buy? History has shown that the stock market is a place where you can earn money, but you can also lose it. However, many experts think that, in the long-term, biotech companies are a safe investment.
